[177Lu]Lu-NeoB

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Breast CancerMetastatic Neuroendocrine Prostate CancerNewly Diagnosed and Recurrent Glioblastoma

Phase 1

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Active, not recruitingNCT05739942

Novartis PharmaceuticalsNewly Diagnosed and Recurrent Glioblastoma

Start: 2024-05-15End: 2032-07-01Updated: 2026-02-03

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

RecruitingNCT05870579

Novartis PharmaceuticalsBreast Cancer

Start: 2023-11-13End: 2032-01-26Target: 48Updated: 2025-08-21

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

RecruitingNCT06247995

Novartis PharmaceuticalsBreast Cancer

Start: 2024-08-14End: 2031-09-09Target: 58Updated: 2025-11-06

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruitingNCT06379217

Novartis PharmaceuticalsMetastatic Neuroendocrine Prostate Cancer

Start: 2024-07-29End: 2026-08-27Updated: 2026-03-11

Related Papers

TIP-22. Trial in progress: A Phase Ib dose-finding study and evaluation of [177Lu]Lu-NeoB plus radiotherapy and temozolomide for newly diagnosed glioblastoma and as a single agent for recurrent glioblastoma

Neuro-Oncology2025-11-01

Abstract P3-10-21: Phase Ib dose-finding study of [177Lu]Lu-NeoB + ribociclib + fulvestrant in patients w/ ER+/HER2- advanced breast cancer (ABC) w/ GRPR expression w/ early relapse from (neo)adjuvant endocrine therapy (ET) or progression on ET + CDK4/6i for ABC

Clinical Cancer Research2025-06-13

Abstract P3-10-17: Phase I/II study of the novel radioligand therapy [177Lu]Lu-NeoB plus capecitabine in patients w/ ER+/HER2- advanced breast cancer (ABC) w/GRPR expression after progression on prior endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i) for ABC

Clinical Cancer Research2025-06-13